2039-47-6Relevant academic research and scientific papers
RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION
-
Paragraph 0107; 0110, (2021/06/26)
Modulators of retinoid acid receptor-alpha (RARα) of formula (I) are provided herein, as well as pharmaceutical compositions and methods relating thereto.
INHIBITORS OF LYSINE METHYL TRANSFERASE
-
, (2015/06/08)
There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases utilizing the compounds of t
Practical synthesis of a chromene analog for use as a retinoic acid receptor alpha antagonist lead compound
Jetson, Rachael,Malik, Neha,Luniwal, Amarjit,Chari, Venkatesh,Ratnam, Manohar,Erhardt, Paul
supporting information, p. 104 - 108 (2013/07/27)
Retinoic acid receptor alpha (RARα) selective compounds may guide the design of drugs that can be used in conjunction with hormonal adjuvant therapy in the treatment of breast cancer. Herein we report a modified synthesis of a known RARα antagonist, 2-fluoro-4-[[[8-bromo-2,2-dimethyl-4-(4- methylphenyl)chroman-6-yl]carbonyl]amino]benzoic acid and a synthesis of its unknown, desfluoro analog, 4-[[[8-bromo-2,2-dimethyl-4-(4-methylphenyl)chroman- 6-yl]carbonyl]amino]benzoic acid. The modified route allows for facile reaction workups, increased yields, lower cost and incorporates a green alternative step. Structure-activity relationship studies determined through functional cell-based assays, demonstrated antagonism to RARα for both compounds. Molecular modeling within the RARα binding pocket was used to compare binding interactions of the desfluoro analog to a known RAR antagonist.
Bi(OTf)3-catalysed prenylation of electron-rich aryl ethers and phenols with isoprene: A direct route to prenylated derivatives
Judd, Katie E.,Caggiano, Lorenzo
supporting information; experimental part, p. 5201 - 5210 (2011/08/07)
Electron-rich aryl ethers and phenols react with isoprene (2-methylbuta-1,3-diene) in the presence of catalytic Bi(OTf)3 at 40 °C to afford the corresponding prenylated or 2,2-dimethylchroman products, respectively, in moderate to good yields.
AMIDE DERIVATIVES
-
Page 73, (2010/02/06)
The invention concerns amide derivatives of Formula (Ia) wherein X is -NHCO- or -CONH-; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
-
, (2008/06/13)
Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.
Identification of highly potent retinoic acid receptor α-selective antagonists
Teng, Min,Duong, Tien T.,Johnson, Alan T.,Klein, Elliott S.,Wang, Liming,Khalifa, Berket,Chandraratna, Roshantha A. S.
, p. 2445 - 2451 (2007/10/03)
The syntheses and full retinoid receptor characterization of a novel series of retinoic acid receptor α (RARα) antagonists, 1-5, are described. These compounds bind with high affinity to RARα but were completely inactive in gene transactivation. They were also potent and effective antagonists of retinoic acid (RA) induced gene transcription at RARα. Compounds 1-5 exhibited varying degrees of selectivity for RARα relative to RARβ/γ, with compound 5 being the most selective in both binding and functional antagonism assays. These compounds will be invaluable tools in delineating the physiological roles of RARα in development and in the adult animal and may themselves be useful therapeutic agents in human diseases associated with RARα.
Chroman esters of phenols and benzoic acids having retinoid-like activity
-
, (2008/06/13)
Retinoid like activity is exhibited by compounds of the formula STR1 wherein the R 1 -R 7 groups are independently H or straight chain or branched chain lower alkyl or cycloalkyl of 1 to 6 carbons; X symbolizes an ester or thioester linkage, Y is cycloalk
Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids
Fatope,Abraham
, p. 1973 - 1977 (2007/10/02)
Five (2,2-dimethylchroman-6-yl)alkanoic acids were synthesized and tested for antigelling activities. It was envisioned that these agents might bind via hydrophobic bonding to nonpolar sites of the 'donor-acceptor' regions of hemoglobin S. Several (2,2-di
SYNTHESIS OF 6-CARBOXY-2,2-DIMETHYLCHROMANS AND CHROMENES
Ahluwalia, V. K.,Jolly, R. S.,Tehim, A. K.
, p. 3673 - 3677 (2007/10/02)
The condensation of hydroxybenzoic acids and their methyl esters with isoprene in the presence of orthophosphoric acid gives corresponding 2,2-dimethylchromans, which can be dehydrogenated with DDQ or NBS to give the corresponding 6-carboxy-2,2-dimethylch
